

**ANGEL BIOTECHNOLOGY HOLDINGS PLC
("Angel" or "the Company")**

Angel and BioEos announce extension of contract

Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, that was recently admitted to AIM, and BioEos Ltd are pleased to announce an extension to the contract signed in 2005. Terms of the contract have not been disclosed.

Under the contract Angel is progressing with process scale-up and production of a vaccine product to be used in clinical trials.

BioEos is developing a novel "Sweet Itch" vaccine for horses that suppresses the allergic response to midge bites, which underlies this condition. Sweet Itch affects approximately 5% of horses in the UK. Currently there are no veterinary pharmaceutical agents specifically approved for the treatment of this condition. Trials with the vaccine are currently being undertaken in the UK with the objective of filing for marketing approval as a veterinary pharmaceutical product in 2007.

This contract takes Angel's current pipeline of projects to ten, three of which have been signed in the last three months.

Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings plc, said: "We are very pleased to be continuing work with BioEos, a young enterprising UK biotech firm. It is particularly pleasing to have signed an extended contract with them as Angel's objective is to form long term relationships with clients and we look forward to the opportunity to work with BioEos on other products in its pipeline in the future."

Alan Stuttle, Chief Executive Officer of BioEos commented: "Angel has provided us with valuable expertise and support for scale-up and large volume manufacture of our veterinary trial product. The team at Angel have worked very effectively to ensure that our timelines have been met and this is much appreciated. BioEos also looks forward to a long term relationship with Angel for our current and future products."

-Ends-

Cont'd...

For further information, please call:

Angel Biotechnology Holdings plc

Tel 01670 591920

Gordon Sherriff – COO

Tel 07951 057016

Buchanan Communications

Lisa Baderoon/Mary-Jane Johnson

Tel 020 7466 5000

BioEos Ltd

Alan Stuttle – CEO

Tel 020 7679 9835

About Angel Biotechnology Holdings plc

Angel Biotechnology Holdings plc is a fast growing biomanufacturing company offering process development services and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.

Angel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo, SmithKline Beecham and Serologicals Inc.

Angel operates out of two sites, at Cramlington near Newcastle upon Tyne and at Pentlands Science Park, near Edinburgh.

Angel was established in 2000 and listed on AIM in November 2005.

About BioEos Ltd

BioEos is developing and commercialising a range of novel immuno-modulator products arising from extensive studies within University College London (UK) and the University of Rosario (Argentina). The company, which was established in 2004, is actively pursuing applications for its products in a variety of areas encompassing livestock and veterinary uses in addition to treatment of human medical conditions.

BioEos will be locating to purpose-built premises, in the south of England, in early 2006. The company boasts a management team with a wealth of experience in scientific, technical and medical areas in addition to the successful commercial exploitation of intellectual property.